Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)-MedSci.cn

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

Hasegawa, T; Ariyasu, R; Tanaka, H; Saito, R; Kawashima, Y; Horiike, A; Sakatani, T; Tozuka, T; Shiihara, J; Saiki, M; Tambo, Y; Sonoda, T; Miyazaki, A; Uematsu, S; Tsuchiya-Kawano, Y; Yanagitani, N; Nishino, M

Ariyasu, R (通讯作者)，Canc Inst Hosp Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan.

Abstract

PurposeFor patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvaluma......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

科室

工具

服务